Authors
Yifan Ma, Simeng Zhang, Dongyang Zhang, Zhongyan Hua, Zhijie Li
Published in
Redox report : communications in free radical research. Volume 31. Issue 1. Pages 2702136. Dec 31, 2026. Epub Jul 13, 2026.
Abstract
Neuroblastoma (NB) is a common pediatric extracranial solid tumor. Dimethylaminomicheliolide (DMAMCL), a prodrug of Micheliolide (MCL), shows antitumor activity against NB, but its mechanisms remain unclear. This study investigated the antitumor mechanisms of DMAMCL in NB.
Key pathways/genes were identified by RNA-seq and ferroptosis PCR array. Ferroptosis was confirmed by indicators. Mechanisms were investigated using siRNAs, shRNAs, and overexpression plasmids in vitro and in vivo. Direct targets were screened by LiP-MS. Molecular biology experiments elucidated the mechanisms.
DMAMCL induced ferroptosis in NB in vitro and in vivo, upregulating HMOX1. HMOX1 knockdown attenuated DMAMCL-induced ferroptosis and its overexpression triggered ferroptosis in MYCN-amplified NB cells but not in MYCN-nonamplified cells. DMAMCL-induced ferroptosis via HMOX1 upregulation depended on MYCN levels. Mechanistically, DMAMCL bound to KEAP1 in MYCN-amplified NB cells, increasing nuclear NRF2 and upregulating HMOX1. In MYCN-nonamplified NB cells, DMAMCL upregulated STEAP3, increasing Fe2+ and lipid peroxidation to induce ferroptosis. STEAP3 overexpression induced ferroptosis and suppressed tumor growth.
DMAMCL induces ferroptosis in NB through MYCN-associated dual pathways, activating the NRF2/HMOX1 axis via KEAP1 binding in MYCN-amplified cells, while upregulating STEAP3 in MYCN-nonamplified cells. This provides new insights for DMAMCL application in treating NB subtypes with different MYCN levels.
PMID:
42444025
Bibliographic data and abstract were imported from PubMed on 14 Jul 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 8
- Comments 0